{"id":"NCT00403546","sponsor":"Donald C. Goff, MD","briefTitle":"High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms","officialTitle":"High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2006-11-23","resultsPosted":"2017-06-06","lastUpdate":"2017-06-06"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Ziprasidone 80-160 mg/d","otherNames":["Geodon"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Ziprasidone 160 mg/d","otherNames":["Geodon"]}],"arms":[{"label":"High-Dose Ziprasidone","type":"EXPERIMENTAL"},{"label":"Placebo, Standard Treatment Ziprasidone","type":"PLACEBO_COMPARATOR"}],"summary":"The primary aims of this study are to assess tolerability of ziprasidone dose escalation to 320 milligrams per day (mg/d) compared to continued standard treatment (placebo) as measured by the Side Effect Checklist, Simpson Angus Scale for Extrapyramidal Symptoms (SAS), Barnes Akathisia Scale (BAS), serum prolactin concentrations, vital signs, electrocardiogram (EKG) and completion rates and to assess whether ziprasidone dose escalation improves overall psychopathology compared to continued standard treatment as measured by the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score and response rates as defined by a 20% or greater reduction in PANSS total score.\n\nThe secondary aims of this study are to assess whether ziprasidone dose escalation improves psychotic symptoms compared to continued standard treatment as measured by the Positive Symptom Subscale of the PANSS, to assess whether ziprasidone dose escalation improves negative symptoms compared to standard treatment as measured by the Negative Symptom Subscale of the PANSS, to assess whether ziprasidone dose escalation improves depressive symptoms compared to continued standard treatment as measured by the Calgary Depression Rating Scale (CDRS), and to assess whether ziprasidone dose escalation improves overall functioning with the Clinical Global Impression - Severity (CGI-S), Clinical Global Impression - Improvement (CGI-I), Global Assessment of Functioning (GAF) and the Schizophrenia Cognition Rating Scale (SCoRS).","primaryOutcome":{"measure":"Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial","timeFrame":"From Baseline up to Week 8","effectByArm":[{"arm":"High-Dose Ziprasidone","deltaMin":633,"sd":null},{"arm":"Placebo, Standard Treatment Ziprasidone","deltaMin":588,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":131},"commonTop":["Hypertension","Somnolence","Insomnia","Tachycardia","Dry mouth"]}}